Balancing Access to Medicines and Sustainability in Europe: an Analysis from the Network of Competent Authorities on Pricing and Reimbursement (CAPR)MedicinesAccessInnovationEuropean CooperationCAPR NetworkPricing and ReimbursementThis article discusses pharmaceutical pricing and reimbursement policies in European...
Proposal for a regulation on health technology assessment in Europe: opinions of policy makers, payers and academics from the field of HTA. Expert Rev Pharmacoecon Outcomes Res. 2019;19(3):251–61. PubMed Google Scholar WHO Europe. Medicines reimbursement policies in Europe. http://www.euro...
Currently there are no government price controls over private sector purchases, but federal legislation requires pharmaceutical manufacturers to pay prescribed rebates on certain drugs in order to be eligible for reimbursement under Medicaid and other federal healthcare programmes. In Europe, historically ...
The Biden administration has asked HHS to study whether new reimbursement policies could be used to shore up domestic supplies of critical medicines, including the possibility of new federal payment policies that hike profit margins for certain generic sterile injectables and cancer drugs, procurement ...
The register includes data on all visits to private healthcare for which public reimbursement from NHI has been received. Among other things, information on the patient, the physician and the date of the visit are recorded in the register [54]. Information on demographic variables (age, sex) ...
Prescription of high-cost medicines in French Hospitals: Regulation and procedures of reimbursement The high cost of several drugs or medical devices Benbekhaled,Khaled,Le,... - 《Bulletin Du Cancer Journal De Lassociation Francaise Pour Letude Du Cancer》 被引量: 0发表: 2016年 Analysis of pres...
Price cut was calculated by comparing the reimbursement price negotiated against the lowest provincial bid price before negotiation Source: External Interview; IQVIA analysis Key takeaways • Newly-launched drugs in recent years have more reimbursement opportunities to be included by negotiation • ...
The study also explored whether the European countries studied had implemented policies to regulate decisions relating to the pricing and reimbursement of rare medicines specifically. Typically, no policies applicable to rare medicines alone were in place; instead, decisions on rare medicines were made ...
Policies that "de-link" the financing of R&D from the price of medicines merit further attention, since they can reward innovation while exploiting robust competition in production to generate the lowest sustainable prices. However, in special cases - such as when market volumes are very small or...
that generic drugs cannot be listed for reimbursement until the patent is expired. But in the name of secondary patents, the generics have to wait until its expiry as well.Footnote41 On 1 July 2019, Regulation UE 2019/933 introduced some amendments to the previous Regulation (EC) 469/2009 ...